Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Inclusion Criteria DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumor that is unresponsive to currently available therapies or for which no known effective treatment exists * Measurable or evaluable disease * Must have clinical or radiological evidence of disease * Disease must be accessible to biopsy and imaging studies * No known brain metastases PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Eastern Cooperative Oncology Group (ECOG) 0-2 Life expectancy * At least 3 months Hematopoietic * Absolute neutrophil count at least 2,000/mm\^3 * Platelet count at least 100,000/mm\^3 * No prior bleeding disorder Hepatic * Bilirubin no greater than 1.2 mg/dL * alanine aminotransferase test (ALT) and Aspartate Aminotransferase (AST) no greater than 2.5 times upper limit of normal (ULN) * Prothrombin time (PT)/ partial thromboplastin time (PTT) no greater than ULN Renal * Creatinine less than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after study * Willing to be premedicated for delayed contrast-enhanced MRI * No prior claustrophobia * No dementia or altered mental status that would preclude informed consent * No other uncontrolled concurrent illness * No ongoing or active infection * No psychiatric illness or social situations that would preclude study compliance * No immunodeficiency * HIV negative * Must be willing to receive blood products * No thyroid disease * Thyroxine and thyroid-stimulating hormone no greater than ULN PRIOR CONCURRENT THERAPY: Biologic therapy * At least 4 weeks since prior immunotherapy Exclusion Criteria Chemotherapy * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * Prior taxanes allowed * No concurrent chemotherapy Endocrine therapy * No concurrent hormonal therapy except: * Concurrent hormonal replacement therapy * Concurrent medication for maintaining castrate status in patients with progressive hormone refractory prostate cancer Radiotherapy * At least 4 weeks since prior radiotherapy and recovered * No prior radiotherapy to more than 25% of the bone marrow * No concurrent radiotherapy Surgery * More than 4 weeks since prior surgery Other * No other concurrent investigational or commercial agents or therapies for the malignancy * No other concurrent antitumor therapy